Medicine with the active substance Sevelamer hydrochloride (ATC: V03AE02)
Arzneimittel mit dem Wirkstoff Sevelamer hydrochlorid (ATC: V03AE02)
Germany · Magdeburg · how to bid here →
Your path to submission
- Deadline: 31 October — 24 days left. The source says 00:00. That means either only the day is known, or the deadline ends at midnight at the START of that day. To be safe, plan to submit by the day before.
- The submission point is stated in the notice (link on the right).
- Offer and evidence in: DEU.
- Collect your evidence — use the eligibility analysis above: it lists the requirements and, for known certificates, how to get them.
Clement What the numbers say about this buyer
- In this sector the buyer awards roughly every 4 months (36 awards, most recently September 2026) — the next award is due around January 2027 by that rhythm. The last award went to Novo Nordisk Pharma GmbH.n = 36
- 49% of this buyer's awards went to companies that had already won here before (103 awards since 2018, spread over 53 companies). That is well below the sector norm (62%) — this buyer switches suppliers more often than others.n = 103 awards since 2018
- The median procedure drew just one bid (99 procedures with a bid count); 60% ended with a single bidder. Sector: median 2 bids.n = 99
- Across 119 procedures with structured selection criteria, this buyer most often required: Trade register enrolment (118 of 119), Quality management (2 of 119), References: services (2 of 119), Professional liability insurance (2 of 119).n = 119
- Not one of the 103 awards with a known winner country has gone to a foreign company so far. Sector average: 1%.n = 103
From this buyer's documented awards; comparison values from the same sector and country. Not a forecast, not legal advice. As of 04/10/2026.
Foreign bidders
In Germany · Medical equipment & pharma, 265 contracts went to foreign companies over the last 3 years (of 22,200 recorded awards) — mostly from Austria, Netherlands, France.
Submission language: DEU.
Typical field: median 1 (from 106 awards).
What the buyer is looking for
Conclusion of non-exclusive discount agreements pursuant to § 130a(8) SGB V for finished medicinal products with the active substance sevelamer hydrochloride (ATC: V03AE02) at any time as part of an open-house model. A contract is concluded with each pharmaceutical company that meets the requirements for participation. There is no exclusivity. Accession or conclusion of the contract may take place at any time and under the same conditions. Individual contract negotiations are not carried out. The earliest contract start date is 01.01.2025. On this basis, the maximum duration of the contract is 24 months. The contract ends on 31.12.2026 regardless of the beginning of the contract. Should AOK Sachsen-Anhalt tender exclusive contracts for the active substances during the term of the contract in accordance with the relevant procurement law provisions, the contracts concluded within the…
Show full description
… framework of this publication will be terminated in accordance with the contractual provisions. This publication does not constitute the award of a public contract within the meaning of § 103 GWB or public procurement law. Publication in the Supplement to the Official Journal of the European Union shall be carried out in order to ensure as much transparency as possible as regards the intended conclusion of contracts. In the absence of a publication form, the contract notice shall be used. The resulting conceptual requirements, such as the procedural designation "open procedure", are solely due to the use of this notice form and the publication platform. A further meaning, in particular a submission to public procurement regulations, insofar as they are not obligatory for legal reasons, is not associated with this.
What you must prove — eligibility criteria
Contract
Who has won here before
| Company | Awards | Period |
|---|---|---|
| Novartis Pharma GmbH · Nürnberg | 7 | 2013–2026 |
| PIK AG | 5 | 2025 |
| Bayer Vital GmbH · Leverkusen | 5 | 2014–2026 |
| GlaxoSmithKline GmbH & Co. KG · München | 5 | 2012–2026 |
| Pfizer Pharma GmbH · Berlin | 5 | 2023–2026 |
How often this buyer tenders this
Who knows the rhythm prepares instead of reacting.